We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Dolichol Biomarker Evaluated for Congenital Disorders of Glycosylation

By LabMedica International staff writers
Posted on 14 Aug 2020
Print article
The AB MDS SCIEX API4000 tandem mass spectrometer (Photo courtesy of SCIEX).
The AB MDS SCIEX API4000 tandem mass spectrometer (Photo courtesy of SCIEX).
A congenital disorder of glycosylation (CDG; previously called carbohydrate-deficient glycoprotein syndrome) is one of several rare inborn errors of metabolism in which glycosylation of a variety of tissue proteins and/or lipids is deficient or defective.

CDG often cause serious, sometimes fatal, malfunction of several different organ systems (especially the nervous system, muscles, and intestines) in affected infants. Dolichol is a membrane lipid which carries monosaccharides and glycans for N-linked protein glycosylation occurring in the endoplasmic reticulum.

Scientists from the Charles University and General University Hospital (Prague, Czech Republic) analyzed urine samples from 75 controls, six patients with CDG ((NUS1-CDG, SRD5A3-CDG, two with PMM2-CDG, PGM1-CDG, DPAGT1-CDG), and 43 patients with suspicion of CDG. Furthermore, tissue homogenates (frontal cortex, skeletal muscle, heart and liver) from two NUS1-CDG patients and two controls (at the age 0–5 years) were also analyzed. The dolichol ratio determination was established as a non-invasive screening method and evaluated through a screening for rare CDG syndromes.

The urine and tissue samples were processed and homogenized with a 4710 Series Ultrasonic Homogenizer, (Cole Parmer, Vernon Hills, IL, USA). The dolichols (Dol) were analyzed by using the AB MDS SCIEX API4000 tandem mass spectrometer (Applied Biosystems, Foster City, CA, USA) coupled with Agilent 1290 Infinity UPLC System (Agilent Technologies, Santa Clara, CA, USA).

The dolichol 18 to dolichol 19 (Dol18/Dol19) ratio biomarker was compared in urine samples with different CDGs to evaluate its use for identifying these disorders. The investigators reported that in the control group, a significant correlation between the ratio of Dol18/Dol19 and age was found in urine. They established a reference range for Dol18/Dol19 from the urine samples. The ratio of Dol18/Dol19 was significantly higher in both urine and tissue samples from patients with mutation in NUS1 in comparison to controls.

The authors concluded that their results on test samples show a novel diagnostic option for patients with rare congenital disorders of glycosylation, especially for those with pathological mutations in NUS1, who cannot be detected by usual screening methods. The study was published in the August, 2020 issue of the journal Clinica Chimica Acta.


Related Links:

Charles University and General University Hospital
Cole Parmer
Applied Biosystems
Agilent Technologies
Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.